ArticlePathology oncology research : POR2017
Quantification of Circulating Free DNA as a Diagnostic Marker in Gall Bladder Cancer.
Article in Pathology oncology research : POR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 62 citations in OpenAlex.
- Novel Liquid Biopsy in Gastrointestinal Cancers.Journal of gastroenterology and hepatology · 2026Review
- Circulating tumor DNA in biliary tract cancers: A review of current applications.World journal of clinical oncology · 2025Review
- Early detection of gallbladder cancer: Current status and future perspectives.World journal of clinical oncology · 2025Review
- Incidental Gallbladder Cancer: A Comprehensive Review.Journal of gastrointestinal cancer · 2025Review
- Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective.The journal of liquid biopsy · 2024Review
- Clinical Applications of Circulating Tumor DNA Profiling in GI Cancers.JCO oncology practice · 2024Review
- Gallbladder cancer: Progress in the Indian subcontinent.World journal of clinical oncology · 2024Review
- Panel of serum long non-coding RNAs as potential non-invasive biomarkers for gallbladder carcinoma.Non-coding RNA research · 2024Article
- Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics.Journal of experimental & clinical cancer research : CR · 2024Article
- Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications.Cancers · 2024Review
- Diagnostic value of quantification of cell-free DNA for suspected gallbladder cancer.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Review
- Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?Cancers · 2023Review
- Removing different number of regional lymph nodes affects survival outcomes of operable patients at stage IIA non-small cell lung cancer (according to the 8th edition staging).Journal of thoracic disease · 2023Article
- Review
- Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives.Exploration of targeted anti-tumor therapy · 2022Review
- Effect of lymphadenectomy on the prognosis for N0 gallbladder carcinoma patients: A study based on SEER database.Cancer medicine · 2021Article
- Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review.World journal of gastrointestinal oncology · 2021Review
- Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.Diagnostics (Basel, Switzerland) · 2021Article
- Diagnostic value of quantification of circulating free DNA for gall bladder cancer using a chemiluminescence DNA biosensor system based on DNA G-quadruplex/ hemin enzyme.Translational oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gall bladder Carcinoma (GBC) is the fifth most common cancer of the digestive tract and frequently diagnosed in late stage of disease. Estimation of circulating free DNA (cfDNA) in serum has been applied as a "liquid biopsy" in several deep seated malignancies. Its value in diagnosis of gall bladder carcinoma has not been studied. The present study was designed to assess the role of cfDNA in the diagnosis of GBC and correlate levels with the TNM stage. Serum was collected from 34 patients with GBC and 39 age and sex matched controls including 22 cholecystitis and 17 healthy individuals. Serum cfDNA levels were measured through quantitative polymerase chain reaction (qPCR) by amplification of β-globin gene. Performance of the assay was calculated through the receiver operating characteristic (ROC) curve. The cfDNA level was significantly lower in healthy controls and cholecystitis (89.32 ± 59.76 ng/ml, 174.21 ± 99.93 ng/ml) compared to GBC (1245.91 ± 892.46 ng/ml, p = <0.001). The cfDNA level was significantly associated with TNM stage, lymph node involvement and jaundice (0.002, 0.027, and 0.041, respectively). Area under curve of ROC analysis for cancer group versus healthy and cholecystitis group was 1.00 and 0.983 with sensitivity of 100 %, 88.24 % and specificity of 100 % respectively. Quantitative analysis of cfDNA may distinguish cholecystitis and gall bladder carcinoma and may serve as new diagnostic, noninvasive marker adjunct to imaging for the diagnosis of GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.